ArticleTheranostics2021
An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Biomimetic dual-driven STING nanoagonist orchestrates neoadjuvant mild photo-immunotherapy for fibrosarcoma.Materials today. Bio · 2026Article
- Optimizing Exosome Lipid Hybrid Nanoparticles for Enhanced siRNA Delivery and Improved Therapeutic Anticancer Efficacy In Vivo.ACS nano · 2025Article
- Intersection of ferroptosis and nanomaterials brings benefits to breast cancer.Cell biology and toxicology · 2025Review
- Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia.Journal for immunotherapy of cancer · 2025Article
- CD47 Knock-Out Using CRISPR-Cas9 RNA Lipid Nanocarriers Results in Reduced Mesenchymal Glioblastoma Growth In Vivo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Tailored Intranasal Albumin Caged Selegiline-α Synuclein siRNA Liposome with Improved Efficiency in Parkinson's Model.Pharmaceutics · 2025Article
- Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review).Oncology letters · 2024Review
- Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.Bioactive materials · 2024Review
- Evolving Tumor Characteristics and Smart Nanodrugs for Tumor Immunotherapy.International journal of nanomedicine · 2024Review
- Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer.International journal of nanomedicine · 2024Article
- Discovery of Anti-CD47 Peptides as Innate Immune Checkpoint Inhibitors.Advanced therapeutics · 2023Article
- Marine natural product lepadin A as a novel inducer of immunogenic cell death via CD91-dependent pathway.Natural products and bioprospecting · 2023Article
- Review
- Quetiapine Albumin Nanoparticles as an Efficacious Platform for Brain Deposition and Potentially Improved Antipsychotic Activity.Pharmaceutics · 2023Article
- Lipid-based nanoparticles for cancer immunotherapy.Medical review (2021) · 2023Review
- Review
- Design, development, in-vitro and in-vivo evaluation of polylactic acid-based multifunctional nanofibrous patches for efficient healing of diabetic wounds.Scientific reports · 2023Article
- Elimination of Cancer Cells in Co-Culture: Role of Different Nanocarriers in Regulation of CD47 and Calreticulin-Induced Phagocytosis.ACS applied materials & interfaces · 2023Article
- A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy.International journal of nanomedicine · 2023Review
- Emerging Progress of RNA-Based Antitumor Therapeutics.International journal of biological sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Hend Mohamed Abdel-BarInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
Adam A WaltersInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
Yau LimInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
Nadia RouatbiInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
Yue QinInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
Fatemeh GheidariInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
Shunping HanInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
Rihab OsmanFaculty of Pharmacy-Ain Shams University, Abbassia, Cairo, P.O. box: 11566 Egypt.
Julie Tzu-Wen WangInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
Khuloud T Al-JamalInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
King's College London · GB
Funding
Cancer Research UKWellcome TrustWellcome Trust WT103913
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsCalreticulinCD47 AntigenCell Line, TumorDoxorubicinDrug Delivery SystemsDrug LiberationImmunogenic Cell DeathImmunotherapyMacrophagesMaleMiceMice, Inbred BALB CNanoparticle Drug Delivery SystemNeoplasmsPhagocytosisCalreticulinCD47 AntigenDoxorubicinNanoparticle Drug Delivery SystemRNA, Small InterferingcalreticulinCD47doxorubicinImmunogenic cell deathSNALPs
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.